Literature DB >> 11732870

Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma.

G Perea1, A Sureda, R Martino, A Altés, C Martínez, E Cabezudo, B Amill, G A Martín-Henao, Y González, L Muñoz, M Peyret, S Brunet, J Sierra.   

Abstract

We analyzed the prognostic factors for a successful mobilization and peripheral blood stem cell collection in a series of 57 consecutive patients with multiple myeloma (MM); a new scoring system to predict an adequate mobilization in this subset of patients was also constructed. A total of 221 aphereses were performed in 57 patients with MM. The median time from diagnosis to mobilization was 12 months (range 4-120). Only one line of chemotherapy was administered before mobilization to 36 patients and two or more to 21. The median number of alkylating chemotherapy cycles was 6 (2-33). Two patients were mobilized in complete remission, 32 in partial response, and 23 in stable/progressive disease. Significant adverse prognostic factors for collecting 2.5 x 10(6) CD34+cells/kg or more were: a period of at least 12 months from diagnosis, at least six cycles of alkylating agents, and a plasma cell infiltration of 20% or more prior to mobilization. Patients with three risk factors had a probability of only 0.38 (95% CI 0.3-0.9) for adequate mobilization. Ten patients failed to mobilize; a period from diagnosis of 12 months or more and female sex were unfavorable factors. Patients with two risk factors had a probability of 0.50 (95% CI 0.2-0.8) for failing the mobilization procedure. These findings indicate that MM patients must be mobilized early in the course of the disease, with minimal disease burden before severe hematopoietic progenitor cell injury due to cumulative therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732870     DOI: 10.1007/s002770100351

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  12 in total

1.  Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.

Authors:  Nils Winkelmann; Max Desole; Inken Hilgendorf; Thomas Ernst; Herbert G Sayer; Christa Kunert; Lars-Olof Mügge; Andreas Hochhaus; Sebastian Scholl
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-17       Impact factor: 4.553

Review 2.  A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program.

Authors:  D Sheppard; C Bredeson; L Huebsch; D Allan; J Tay
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

Review 3.  Current status of stem cell transplantation for multiple myeloma.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Suzanne Hayman
Journal:  Curr Treat Options Oncol       Date:  2005-05

4.  Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.

Authors:  Ivana N Micallef; Patrick J Stiff; Edward A Stadtmauer; Brian J Bolwell; Auayporn P Nademanee; Richard T Maziarz; Angela M Partisano; Sachin Marulkar; John F DiPersio
Journal:  Am J Hematol       Date:  2013-09-09       Impact factor: 10.047

5.  GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma.

Authors:  Zachary D Crees; Keith Stockerl-Goldstein; Abi Vainstein; Hemda Chen; John F DiPersio
Journal:  Future Oncol       Date:  2019-09-09       Impact factor: 3.404

6.  Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro.

Authors:  M Schmidt-Hieber; A Busse; B Reufi; W Knauf; E Thiel; I W Blau
Journal:  J Cancer Res Clin Oncol       Date:  2008-08-22       Impact factor: 4.553

7.  NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma.

Authors:  B Jeker; U Novak; B Mansouri Taleghani; G M Baerlocher; K Seipel; B U Mueller; M Bigler; D Betticher; J-M Luethi; S Farese; A Ruefer; T Pabst
Journal:  Bone Marrow Transplant       Date:  2017-10-23       Impact factor: 5.483

8.  A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma.

Authors:  Gaofeng Zheng; Jingsong He; Zhen Cai; Donghua He; Yi Luo; Jimin Shi; Guoqing Wei; Jie Sun; Weiyan Zheng
Journal:  Oncol Lett       Date:  2019-12-03       Impact factor: 2.967

9.  Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.

Authors:  S Sinha; D Gastineau; I Micallef; W Hogan; S Ansell; F Buadi; D Dingli; A Dispenzieri; M Gertz; C Greiner; S Hayman; D Inwards; P Johnston; M Lacy; M Litzow; L Porrata; J L Winters; S Kumar
Journal:  Bone Marrow Transplant       Date:  2010-10-11       Impact factor: 5.483

10.  Current role of radiation therapy for multiple myeloma.

Authors:  Giampaolo Talamo; Christopher Dimaio; Kamal K S Abbi; Manoj K Pandey; Jozef Malysz; Michael H Creer; Junjia Zhu; Muhammad A Mir; John M Varlotto
Journal:  Front Oncol       Date:  2015-02-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.